Long noncoding RNA DLX6-AS1 promotes cell growth and invasiveness in bladder cancer via modulating the miR-223-HSP90B1 axis

References

• Wong MCS, Fung FDH, Leung C, et al. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep. 2018;8:1129.
   PubMed Web of Science ®Google Scholar
• Pang C, Guan Y, Li H, et al. Urologic cancer in China. Jpn J Clin Oncol. 2016;46:497–501.
   PubMed Web of Science ®Google Scholar
• Abdollah F, Gandaglia G, Thuret R, et al. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. Cancer Epidemiol. 2013;37:219–225.
   PubMed Web of Science ®Google Scholar
• Jung I, Messing E. Molecular mechanisms and pathways in bladder cancer development and progression. Cancer Control. 2000;7:325–334.
   PubMedGoogle Scholar
• Diamantopoulos MA, Tsiakanikas P, Scorilas A. Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer. Ann Transl Med. 2018;6:241.
   PubMed Web of Science ®Google Scholar
• Balas MM, Johnson AM. Exploring the mechanisms behind long noncoding RNAs and cancer. Noncoding RNA Res. 2018;3:108–117.
   PubMedGoogle Scholar
• Dong P, Xiong Y, Yue J, et al. Exploring lncRNA-mediated regulatory networks in endometrial cancer cells and the tumor microenvironment: advances and challenges. Cancers (Basel). 2019;11(2):E234.
   PubMed Web of Science ®Google Scholar
• Zabolotneva AA, Zhavoronkov A, Garazha AV, et al. Characteristic patterns of microRNA expression in human bladder cancer. Front Genet. 2013;3:310.
   PubMedGoogle Scholar
• Dong F, Xu T, Shen Y, et al. Dysregulation of miRNAs in bladder cancer: altered expression with aberrant biogenesis procedure. Oncotarget. 2017;8:27547–27568.
   PubMedGoogle Scholar
• Dong P, Xiong Y, Yue J, et al. miR-34a, miR-424 and miR-513 inhibit MMSET expression to repress endometrial cancer cell invasion and sphere formation. Oncotarget. 2018;9:23253–23263.
   PubMedGoogle Scholar
• Guo J, Cao R, Yu X, et al. MicroRNA-223-3p inhibits human bladder cancer cell migration and invasion. Tumour Biol. 2017;39:1010428317691678.
   Google Scholar
• Sugawara S, Yamada Y, Arai T, et al. Dual strands of the miR-223 duplex (miR-223-5p and miR-223-3p) inhibit cancer cell aggressiveness: targeted genes are involved in bladder cancer pathogenesis. J Hum Genet. 2018;63:657–668.
   PubMed Web of Science ®Google Scholar
• Yang C, Wu S, Wu X, et al. Overexpression of FGFR2 reversed miR-223-induced UM-UC-3 cell growth and migration inhibition in vitro Silencing circular RNA UVRAG inhibits bladder cancer growth and metastasis by targeting the microRNA-223/fibroblast growth factor receptor 2 axis. Cancer Sci. 2019;110:99–106.
   PubMed Web of Science ®Google Scholar
• Dong P, Xiong Y, Yu J, et al. Control of PD-L1 expression by miR-140/142/340/383 and oncogenic activation of the OCT4-miR-18a pathway in cervical cancer. Oncogene. 2018;37:5257–5268.
   PubMed Web of Science ®Google Scholar
• Wan Q, Dingerdissen H, Fan Y, et al. BioXpress: an integrated RNA-seq-derived gene expression database for pan-cancer analysis. Database (Oxford). 2015;2015:bav019.
   PubMedGoogle Scholar
• Li JH, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(Database issue):D92–7.
   PubMed Web of Science ®Google Scholar
• Huang WY, Hsu SD, Huang HY, et al. MethHC: a database of DNA methylation and gene expression in human cancer. Nucleic Acids Res. 2015;43(Databaseissue): D856–61.
   PubMedGoogle Scholar
• Enokida H, Yoshino H, Matsushita R, et al. The role of microRNAs in bladder cancer. Investig Clin Urol. 2016;57(Suppl 1):S60–76.
   PubMedGoogle Scholar
• Xu Y, Chen Z, Zhang G, et al. HSP90B1 overexpression predicts poor prognosis in NSCLC patients. Tumour Biol. 2016;37:14321–14328.
   PubMedGoogle Scholar
• Rodríguez-Vicente AE, Quwaider D, Benito R, et al. MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL. BMC Cancer. 2015;15:238.
   PubMed Web of Science ®Google Scholar
• Yang Z, Zhuang L, Szatmary P, et al. Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma. Int J Med Sci. 2015;12:256–263.
   PubMed Web of Science ®Google Scholar
• Li G, Cai M, Fu D, et al. Heat shock protein 90B1 plays an oncogenic role and is a target of microRNA-223 in human osteosarcoma. Cell Physiol Biochem. 2012;30:1481–1490.
   PubMedGoogle Scholar
• Caldas-Lopes E, Cerchietti L, Ahn JH, et al. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc Natl Acad Sci U S A. 2009;106:8368–8373.
   PubMed Web of Science ®Google Scholar
• Cerchietti LC, Lopes EC, Yang SN, et al. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat Med. 2009;15:1369–1376.
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Bona RD, Chiosis G, et al. The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1. J Hematol Oncol. 2010;3:40.
   PubMed Web of Science ®Google Scholar
• Zhang N, Meng X, Mei L, et al. LncRNA DLX6-AS1 promotes tumor proliferation and metastasis in osteosarcoma through modulating miR-641/HOXA9 signaling pathway. J Cell Biochem. 2019 Mar 6. [Epub ahead of print]. DOI:10.1002/jcb.28426
   Web of Science ®Google Scholar
• Li X, Zhang H, Wu X. Long noncoding RNA DLX6-AS1 accelerates the glioma carcinogenesis by competing endogenous sponging miR-197-5p to relieve E2F1. Gene. 2019;686:1–7.
   PubMed Web of Science ®Google Scholar
• Yang J, Ye Z, Mei D, et al. Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating miR-497-5p/FZD4/FZD6/Wnt/β-catenin pathway in pancreatic cancer. Cancer Manag Res. 2019;11:4209–4221.
   PubMed Web of Science ®Google Scholar
• Huang Y, Ni R, Wang J, et al. Knockdown of lncRNA DLX6-AS1 inhibits cell proliferation, migration and invasion while promotes apoptosis by downregulating PRR11 expression and upregulating miR-144 in non-small cell lung cancer. Biomed Pharmacother. 2019;109:1851–1859.
   PubMed Web of Science ®Google Scholar
• Sun W, Zhang L, Yan R, et al. LncRNA DLX6-AS1 promotes the proliferation, invasion, and migration of non-small cell lung cancer cells by targeting the miR-27b-3p/GSPT1 axis. Onco Targets Ther. 2019;12:3945–3954.
   PubMedGoogle Scholar
• Zhao J, Liu HR. Down-regulation of long noncoding RNA DLX6-AS1 defines good prognosis and inhibits proliferation and metastasis in human epithelial ovarian cancer cells via Notch signaling pathway. Eur Rev Med Pharmacol Sci. 2019;23(8):3243–3252.
   PubMed Web of Science ®Google Scholar
• You Q, Shi HY, Gong CF, et al. Long non-coding RNA DLX6-AS1 acts as an oncogene by targeting miR-613 in ovarian cancer. Eur Rev Med Pharmacol Sci. 2019 Aug;23(15):6429–6435. .
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhang CD, Zhang C, et al. DLX6-AS1/miR-204-5p/OCT1 positive feedback loop promotes tumor progression and epithelial-mesenchymal transition in gastric cancer. Gastric Cancer. 2019 Aug 28. Epub ahead of print. DOI:10.1007/s10120-019-01002-1
   Web of Science ®Google Scholar
• Wu DM, Zheng ZH, Zhang YB, et al. Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells. J Exp Clin Cancer Res. 2019;38(1):237.
   PubMedGoogle Scholar